M A Liss1, J M Schenk2, A V Faino2, L F Newcomb3, H Boyer3, J D Brooks4, P R Carroll5, A Dash6, M D Fabrizio7, M E Gleave8, P S Nelson3, M L Neuhouser2, J T Wei9, Y Zheng2, J L Wright3, D W Lin3, I M Thompson1. 1. Department of Urology, University of Texas Health Science Center San Antonio, San Antonio, TX, USA. 2. Fred Hutchinson Cancer Research Center, Seattle, WA, USA. 3. Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA. 4. Stanford University, Stanford, CA, USA. 5. University of California at San Francisco, San Francisco, CA, USA. 6. University of Washington, Seattle, WA, USA. 7. Eastern Virginia Medical School, Norfolk, VA, USA. 8. University of British Columbia, Vancouver, BC, Canada. 9. University of Michigan, Ann Arbor, MI, USA.
Abstract
BACKGROUND: Obesity is a risk factor for incident prostate cancer (PC) as well as risk of disease progression and mortality. We hypothesized that men diagnosed with lower-risk PC and who elected active surveillance (AS) for their cancer management would likely initiate lifestyle changes that lead to weight loss. METHODS: Patients were enrolled in the Prostate Active Surveillance Study (PASS), a multicenter prospective biomarker discovery and validation study of men who have chosen AS for their PC. Data from 442 men diagnosed with PC within 1 year of study entry who completed a standard of care 12-month follow-up visit were analyzed. We examined the change in weight and body mass index (BMI) over the first year of study participation. RESULTS: After 1 year on AS, 7.5% (33/442) of patients had lost 5% or more of their on-study weight. The proportion of men who lost 5% or more weight was similar across categories of baseline BMI: normal/underweight (8%), overweight (6%) and obese (10%, χ2 test P=0.44). The results were similar for patients enrolled in the study 1 year or 6 months after diagnosis. By contrast, after 1 year, 7.7% (34/442) of patients had gained >5% of their weight. CONCLUSIONS: Only 7.5% of men with low-risk PC enrolled in AS lost a modest (⩾5%) amount of weight after diagnosis. Given that obesity is related to PC progression and mortality, targeted lifestyle interventions may be effective at this 'teachable moment', as men begin AS for low-risk PC.
BACKGROUND:Obesity is a risk factor for incident prostate cancer (PC) as well as risk of disease progression and mortality. We hypothesized that men diagnosed with lower-risk PC and who elected active surveillance (AS) for their cancer management would likely initiate lifestyle changes that lead to weight loss. METHODS:Patients were enrolled in the Prostate Active Surveillance Study (PASS), a multicenter prospective biomarker discovery and validation study of men who have chosen AS for their PC. Data from 442 men diagnosed with PC within 1 year of study entry who completed a standard of care 12-month follow-up visit were analyzed. We examined the change in weight and body mass index (BMI) over the first year of study participation. RESULTS: After 1 year on AS, 7.5% (33/442) of patients had lost 5% or more of their on-study weight. The proportion of men who lost 5% or more weight was similar across categories of baseline BMI: normal/underweight (8%), overweight (6%) and obese (10%, χ2 test P=0.44). The results were similar for patients enrolled in the study 1 year or 6 months after diagnosis. By contrast, after 1 year, 7.7% (34/442) of patients had gained >5% of their weight. CONCLUSIONS: Only 7.5% of men with low-risk PC enrolled in AS lost a modest (⩾5%) amount of weight after diagnosis. Given that obesity is related to PC progression and mortality, targeted lifestyle interventions may be effective at this 'teachable moment', as men begin AS for low-risk PC.
Authors: Jason T Newsom; Nathalie Huguet; Michael J McCarthy; Pamela Ramage-Morin; Mark S Kaplan; Julie Bernier; Bentson H McFarland; Jillian Oderkirk Journal: J Gerontol B Psychol Sci Soc Sci Date: 2011-10-09 Impact factor: 4.077
Authors: Jeffrey J Tosoian; Bruce J Trock; Patricia Landis; Zhaoyong Feng; Jonathan I Epstein; Alan W Partin; Patrick C Walsh; H Ballentine Carter Journal: J Clin Oncol Date: 2011-04-04 Impact factor: 44.544
Authors: William J Aronson; Naoko Kobayashi; R James Barnard; Susanne Henning; Min Huang; Patricia M Jardack; Bingrong Liu; Ashley Gray; Junxiang Wan; Ramdev Konijeti; Stephen J Freedland; Brandon Castor; David Heber; David Elashoff; Jonathan Said; Pinchas Cohen; Colette Galet Journal: Cancer Prev Res (Phila) Date: 2011-10-25
Authors: Wendy Demark-Wahnefried; Elizabeth A Platz; Jennifer A Ligibel; Cindy K Blair; Kerry S Courneya; Jeffrey A Meyerhardt; Patricia A Ganz; Cheryl L Rock; Kathryn H Schmitz; Thomas Wadden; Errol J Philip; Bruce Wolfe; Susan M Gapstur; Rachel Ballard-Barbash; Anne McTiernan; Lori Minasian; Linda Nebeling; Pamela J Goodwin Journal: Cancer Epidemiol Biomarkers Prev Date: 2012-06-13 Impact factor: 4.254
Authors: William L Haskell; I-Min Lee; Russell R Pate; Kenneth E Powell; Steven N Blair; Barry A Franklin; Caroline A Macera; Gregory W Heath; Paul D Thompson; Adrian Bauman Journal: Med Sci Sports Exerc Date: 2007-08 Impact factor: 5.411
Authors: Lisa F Newcomb; James D Brooks; Peter R Carroll; Ziding Feng; Martin E Gleave; Peter S Nelson; Ian M Thompson; Daniel W Lin Journal: Urology Date: 2009-09-16 Impact factor: 2.649
Authors: Jan-Erik Johansson; Ove Andrén; Swen-Olof Andersson; Paul W Dickman; Lars Holmberg; Anders Magnuson; Hans-Olov Adami Journal: JAMA Date: 2004-06-09 Impact factor: 56.272
Authors: Kerry N L Avery; Jenny L Donovan; Rebecca Gilbert; Michael Davis; Pauline Emmett; Liz Down; Steven Oliver; David E Neal; Freddie C Hamdy; J Athene Lane Journal: Cancer Causes Control Date: 2013-03-22 Impact factor: 2.506
Authors: Michael A Liss; Lanette Rickborn; John DiGiovanni; Dean Bacich; Linda A DeGraffenried; Manish Parihar; Ian M Thompson; Zelton Dave Sharp Journal: Med Hypotheses Date: 2018-06-05 Impact factor: 1.538
Authors: Susanne M Henning; Colette Galet; Kiran Gollapudi; Joshua B Byrd; Pei Liang; Zhaoping Li; Tristan Grogan; David Elashoff; Clara E Magyar; Jonathan Said; Pinchas Cohen; William J Aronson Journal: Prostate Cancer Prostatic Dis Date: 2017-12-04 Impact factor: 5.554